

Mitochondria in neurogenesis: Implications for mitochondrial diseases

Dario Brunetti^{1,2}  | Werner Dykstra³ | Stephanie Le⁴ | Annika Zink⁴ | Alessandro Prigione^{3,4} 

¹Mitochondrial Medicine Laboratory, Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy

²Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico "C. Besta", Milan, Italy

³Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany

⁴Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany

Correspondence

Alessandro Prigione, MD, PhD, Department of General Pediatrics, Neonatology and Pediatric Cardiology, Heinrich Heine University (HHU), Düsseldorf, Germany.
Email: alessandro.prigione@hhu.de

Present address

Werner Dykstra, Department of Translational Neuroscience, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands

Funding information

Bundesministerium für Bildung und Forschung, Grant/Award Number: AZ.031L0211; Deutsche Forschungsgemeinschaft, Grant/Award Number: PR1527/5-1; United Mitochondrial Disease Foundation, Grant/Award Number: Leigh syndrome roadmap; University Hospital Düsseldorf

Abstract

Mitochondria are organelles with recognized key roles in cellular homeostasis, including bioenergetics, redox, calcium signaling, and cell death. Mitochondria are essential for neuronal function, given the high energy demands of the human brain. Consequently, mitochondrial diseases affecting oxidative phosphorylation (OXPHOS) commonly exhibit neurological impairment. Emerging evidence suggests that mitochondria are important not only for mature postmitotic neurons but also for the regulation of neural progenitor cells (NPCs) during the process of neurogenesis. These recent findings put mitochondria as central regulator of cell fate decisions during brain development. OXPHOS mutations may disrupt the function of NPCs and thereby impair the metabolic programming required for neural fate commitment. Promoting the mitochondrial function of NPCs could therefore represent a novel interventional approach against incurable mitochondrial diseases.

KEYWORDS

iPSCs, mitochondria, mitochondrial diseases, neurogenesis, NPCs

Significance statement

This study discusses the emerging role of mitochondria for neural progenitor cells and for the regulation of cell fate decisions during neurogenesis. Elucidating the importance of mitochondria in neurogenesis might be instrumental to identify interventional targets for mitochondrial diseases, a group of rare incurable disorders causing neurological and neurodevelopmental defects.

1 | INTRODUCTION

Mitochondria are dynamic double-membrane organelles that are classically considered to be the powerhouse of the cell for their production of adenosine triphosphate (ATP) through the process of oxidative phosphorylation (OXPHOS).¹ At the same time, mitochondria are involved in several additional tasks, including calcium

and free radical signaling, apoptosis, and metabolite-mediated modulation of gene expression.² Hence, mitochondria can act as gatekeepers of cellular homeostasis and can regulate cell death pathways to preserve cellular fitness and maintain genome integrity.^{3,4}

In the past few years, several works investigated the role of mitochondria in stem cell reprogramming and differentiation.⁵⁻⁷

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. STEM CELLS published by Wiley Periodicals LLC on behalf of AlphaMed Press.

Undifferentiated stem cells mainly rely on glycolytic metabolism for energy generation and exhibit mitochondria with a roundish morphology.⁸ During the differentiation process, mitochondria acquire a fused morphology and the metabolism switches from glycolysis to OXPHOS.^{9,10} Conversely, somatic cells generally depend on OXPHOS and show a fused mitochondrial network, which reverts to a stem cell-like state upon reprogramming into induced pluripotent stem cells (iPSCs).^{9,11,12}

Among somatic cells, neurons are known to be highly dependent on mitochondrial function, given the high energy demand of the brain, which consumes around 20% of energy at rest despite weighting only around 2% of the entire human body.¹³ Recent evidence indicates that mitochondria could play a role not only in energetically demanding mature cells like neurons, but also in governing cell fate decisions during the establishment of physiological neurogenesis.¹⁴⁻¹⁷

Here, we focus on the emerging role of mitochondria for neurogenesis and for the function of neural progenitor cells (NPCs). We discuss the impact of these recent findings in the context of mitochondrial diseases. Mitochondrial diseases are currently incurable and the mechanisms underlying their neuronal pathology remain to be fully understood.

2 | MITOCHONDRIA IN CELL FATE DECISION: BIOENERGETICS AND BEYOND

The OXPHOS process occurs at the level of the mitochondrial inner membrane through five membrane protein complexes. As mitochondrial complexes shuttle electrons from one to another, protons are pumped into the inner mitochondrial matrix. This creates a proton gradient along the inner mitochondrial membrane, known as mitochondrial membrane potential (MMP).¹⁸ The release of protons through the mitochondrial complex V, and their conversion into water in the presence of oxygen, enables the final generation of ATP.¹⁹

Mitochondria dynamically regulate their structural morphology through fusion or fission of the outer and inner mitochondrial membrane in a coordinated manner.²⁰ This is orchestrated by the dynamin-related GTPases Mitofusin 1 (MFN1), Mitofusin 2 (MFN2), optic atrophy protein 1 (OPA1), and Dynamin-related protein 1 (DRP1).^{21,22} Also cristae membranes, once thought to be static under physiological conditions, can rapidly reshape their ultrastructural morphology.²³ The coordinated modifications of mitochondrial shape and cristae architecture can play a critical role in the cellular regulation of bioenergetic outputs and in the cellular adaptation to environmental cues and changing demands.^{24,25}

OXPHOS is under dual genetic control.²⁶ The majority of mitochondrial complex proteins are encoded by the nuclear DNA, while 13 protein subunits are encoded by the mitochondrial DNA (mtDNA). mtDNA, a circular 16.5 kb-long genome, also encodes two rRNAs and 22 tRNAs for mtDNA translation.²⁷ mtDNA does not exhibit introns or histones, and it is present in multiple copies in mammalian cells. When an mtDNA mutation occurs, the mutation can be present in all mtDNA molecules (a situation known as homoplasmy) or only in a portion of the mtDNA molecules (a situation known as heteroplasmy).²⁸ Since mtDNA is inherited

through the maternal lineage, mtDNA mutations can be passed from mother to offspring. However, the proportion of mutated molecules can vary dramatically among the children. This phenomenon is usually explained by the so-called mtDNA bottleneck, that is, the presence of a sudden reduction of mtDNA copies from primordial germ cells during the production of primary oocytes that changes the ratio between mutated and wild-type mtDNA molecules.²⁹ For this reason, a healthy mother carrying mtDNA mutations at low heteroplasmy could give birth to healthy children with low levels of heteroplasmy, as well as to affected children carrying pathogenically high levels of heteroplasmy.

The number of mtDNA copies can also vary among individual cells. Energetically demanding cells like neurons and cardiomyocytes possess elevated mtDNA copy number, while less active cells usually exhibit low amount of mtDNA copies. Undifferentiated stem cells usually contain low mtDNA copy number, which gradually increases during differentiation.^{9,30} A major mechanism governing mtDNA copy number in cells is nuclear transcription-mediated mitochondrial biogenesis.³¹ The master regulator of mitochondrial biogenesis is PPAR-gamma Coactivator 1 alpha (PGC-1a), a transcriptional coactivator induced in the cells by shortage of energy or by increased energy demands.^{32,33} Low ATP levels are sensed by AMP-dependent kinase (AMPK), which responds by switching on mechanisms to increase energy output, including PGC-1a. AMPK can activate PGC-1a through SIRT1-mediated deacetylation or through direct phosphorylation.^{34,35} Once activated, PGC-1a induces nuclear respiratory factors (NRF1 and NRF2) to promote the expression of OXPHOS-related genes.³⁶

Besides bioenergetics, mitochondria perform a plethora of functions that contribute to the regulation of cellular homeostasis. Mitochondria are involved in the generation of reactive oxygen species (ROS), calcium balance, and apoptotic cells death.^{3,37} ROS and calcium are important second messengers involved in cellular signaling.³⁸ However, excessive ROS production that cannot be counterbalanced by the antioxidant capacity of the cell can result in macromolecular damage.³⁹ Similarly, disproportionate intramitochondrial accumulation of calcium can cause the opening of the mitochondrial permeability transition pore, leading to the collapse of the MMP and the initiation of the apoptotic cascade.⁴⁰ In the context of stem cells, ROS are implicated in promoting differentiation through activation of a nuclear transcriptional program that alters gene expression profiles.⁴¹⁻⁴³ Indeed, ROS mediated damage and antioxidant levels increase during stem cell differentiation and decrease upon reprogramming to iPSCs.^{9,44}

Mitochondrial metabolites generated in the mitochondria through the tricarboxylic (TCA) cycle can also function as cofactors or substrates for chromatin modifying enzymes. Hence, the amount of mitochondrial activity and related levels of metabolites can influence the global epigenetic landscape of the cells through the regulation of nuclear gene expression.⁴⁵ Through this crosstalk between energy metabolism and gene regulation, mitochondrial activity can thus contribute to the regulation of cell fate identity and plasticity.⁶

3 | MITOCHONDRIA IN NEUROGENESIS

Of all cell types in the central nervous system (CNS), neurons have the highest energy demands.⁴⁶ The majority of ATP generated in the CNS is utilized to maintain neuronal excitability and overall synaptic function.⁴⁷ In order to maximize local energy generation, mitochondria can be anchored at dendrites and synapses to synthesize ATP, thereby fueling vesicle recycling during neuronal activity.⁴⁸ However, in addition to postmitotic neurons, mitochondrial OXPHOS might also play a crucial role during neurogenesis.^{16,49}

Neurogenesis is the process in which new neurons are formed from NPCs.^{50,51} NPCs can be defined as the precursor cell population in the CNS giving rise to neuronal cells and glial cells that include oligodendrocytes and astrocytes.⁵² Importantly, mammalian NPCs can be present not only during embryonic brain development,⁵³ but also in neonatal and mature adult brain.^{51,54} However, to what extent neurogenesis is maintained during human adulthood still remains a matter of debate.⁵⁵⁻⁵⁷

In the process of generating neurons, the metabolic program undergoes critical changes. Undifferentiated stem cells mainly rely on glycolysis,^{9,58} while neurons are highly dependent on mitochondrial OXPHOS.⁵⁹ Single-cell transcriptomics of adult mouse NPCs revealed the activation of an OXPHOS signature during the initiation of neurogenesis.⁶⁰ The acquisition of such metabolic program could represent an important factor for the evolution of the human brain size.⁶¹ The human brain contains an expanded pool of progenitors compared to rodents, which could contribute to the extension of brain size, and exhibit higher basal energy expenditures compared to primates, which might provide sufficient energy for larger brains and faster reproduction while maintaining homeostatic functions and longevity.⁶¹

In order to acquire an OXPHOS metabolic profile, mitochondria in differentiating neuronal cells increase in number, and develop an elongated morphology with a dense network appearance.^{62,63} During mouse embryonic neurogenesis, mitochondria in intermediate progenitor cells appear more fragmented than in undifferentiated neural stem cells.⁶⁴ Conversely, in adult neurogenesis mitochondria in intermediate progenitor cells show increased fused morphology compared to undifferentiated neural stem cells.⁶⁵ Despite these minor differences, it is widely accepted that mitochondria undergo changes during neurogenesis to eventually acquire an elongated morphology in neurons.^{15,17}

Until recently, the above-mentioned changes in energy metabolism and mitochondrial morphology were considered as one of the by-products of neuronal differentiation, together with changes in cell cycle, communication, and signaling.^{15,66} However, recent data in mouse embryonic NPCs and human iPSC-derived NPCs revealed that changes in mitochondrial dynamics are instrumental in initiating neurogenesis.¹⁴ During cell division, NPCs can either self-renew or exit from stemness to begin neuronal differentiation. Interestingly, those NPCs with fragmented mitochondria are the ones that are poised to become neurons, while those with fused mitochondria are destined to self-renew and maintain stemness.¹⁴ The time window for this decision point was found to be 3 to 6 hours for mouse NPCs and 6 to 12 hours for human NPCs.¹⁴ These new findings provide a causal link between mitochondrial remodeling and mammalian neurogenesis,

suggesting new potential targets for neurological diseases in which mitochondrial function is impaired.

In agreement with this new role of mitochondrial dynamics in instructing neurogenesis, recent works highlighted the importance of mitochondrial metabolism for neurogenesis. Adult neurogenesis requires mitochondrial activity, as proliferating mouse intermediate progenitors become dependent on OXPHOS, and OXPHOS disruption in mice can induce premature aging phenotypes.^{65,67} Indeed, human iPSC-derived NPCs exhibit fused mitochondria, and a reduction of glycolytic metabolism coupled with increased OXPHOS.⁶⁸ Proliferating mouse adult NPCs also express high endogenous ROS levels, suggestive of elevated mitochondrial activity.⁶⁹ Redox regulation impacts physiological neurogenesis,⁶⁹ and may play a role in NPCs for balancing between stemness and differentiation.⁷⁰ Increasing the glycolytic reliance of NPCs can prevent their neuronal commitment, as seen for example in mouse embryonic NPCs expressing low levels of the RNA-binding protein Sam68.⁷¹ Accordingly, the impairment of mitochondrial function in mouse embryonic NPCs causes calcium dyshomeostasis and delayed cortical neurogenesis.⁷² Inhibition of mitochondrial function also disrupt the generation of neurons from human embryonic stem cells.⁷³

Mitochondrial function may not only be crucial for the activity and survival of postmitotic neurons and for safeguarding the ability of NPCs to commit to neuronal cell fate, but also for ensuring the physiological homeostasis of NPCs (Figure 1). Mitochondrial function in embryonic and adult mice was found essential not only for ensuring proper NPC differentiation but also for allowing their maintenance of self-renewing capacity.⁷⁴ Two recent studies identified that two proteins that are crucial for neurogenesis, and specifically for neocortex expansion, namely MCPH1 and ARHGAP11B, act in the mitochondria of NPCs.^{75,76} Hence, the mitochondrial function of NPCs may play a pivotal role for mammalian neurogenesis and neocortical growth.⁷⁷

For the proper generation of neurons, which are highly complex and polarized cells, it is essential to establish a proper morphology for dendrites, axons, and synapses. This process is known as neuronal morphogenesis.⁷⁸ Mitochondria may play an important role during neuronal morphogenesis.⁷⁹ Mitochondria are present at synaptic terminals during the time synaptic connections are formed.^{80,81} Mitochondria also contribute to the coordination of axon branching sites through localized axonal protein synthesis.⁸² Depletion of mitochondria during neuronal morphogenesis can lead to defects in synaptic plasticity and spine morphology.^{48,83}

Taken together, dysfunctions in the regulation of mitochondrial dynamics and morphology or defective OXPHOS bioenergetics could have profound effects on physiological neurogenesis and on the proper establishment of neuronal function.

4 | NEURAL PROGENITOR CELLS AS POTENTIAL INTERVENTIONAL TARGETS FOR MITOCHONDRIAL DISEASES

One of the major causes of mitochondrial dysfunction in humans is represented by mitochondrial diseases, a group of rare genetic




FIGURE 1 Mitochondrial pathways in cell fate decisions and neurogenesis. Mitochondria undergo changes during the commitment and differentiation of neural progenitor cells (NPCs). We here depict some of these changes highlighting distinct functions and mechanisms in different colors. MMP, mitochondrial membrane potential; ROS, reactive oxygen species

disorders caused by mutations in nuclear DNA genes or mtDNA genes encoding for proteins involved in OXPHOS functionality and structural assembly, mtDNA replication, mitochondrial transcription and translation, and mitochondrial dynamics.^{26,84} Mitochondrial diseases affect approximately 1 in 4000 newborns, and typically cause neurological symptoms including psychomotor regression, stroke-like episodes, dementia, and epilepsy (Table 1).^{84,85} Not only is the CNS a major target in primary genetically determined mitochondrial diseases, but mitochondrial dysfunction is also a prominent feature in many of the most prevalent neurodegenerative diseases.⁸⁶

Although in the past 30 years mitochondrial medicine has made enormous progresses in understanding the genetic and biochemical pathomechanisms of mitochondrial disorders,^{87,88} current treatments still remain focused on controlling complications and reducing the symptoms.^{89,90} The lack of effective therapies for most mitochondrial diseases is due to several problems, including a specific lack of effective preclinical models for performing drug discovery.⁹¹ The lack of disease models has limited the identifications of adequate markers and useful clinical outcomes, and it also prevented a more detailed understanding of the mechanisms underlying the neuronal pathology associated with mitochondrial diseases.

Based on the current mechanistic understanding, the neurological defects caused by mitochondrial diseases are mainly attributed to the degeneration of postmitotic neurons.^{84,85} However, given the above-mentioned studies implicating mitochondria in the homeostatic

regulation of NPCs and neurogenesis, it is possible that NPCs dysfunction may play an important yet underappreciated contributing role in the development of mitochondrial diseases. Accordingly, mitochondrial diseases can exhibit neurodevelopmental manifestations, such as developmental delay and cognitive impairment.⁹²⁻⁹⁴

The use of patient-derived iPSCs is providing important new insights that can shed light on the role of NPCs in the neuronal pathogenesis of mitochondrial diseases. NPCs generated from patients with mitochondrial diseases carrying mutations associated with Leigh syndrome (LS) in the mtDNA gene *MT-ATP6* (mitochondrially encoded ATP synthase membrane subunit 6) exhibited defective OXPHOS bioenergetics and aberrant calcium homeostasis.^{68,95} Cerebral organoids derived from LS patients carrying mutations in the mtDNA gene *MT-ATP6* or in the nuclear genes *PDH* (pyruvate dehydrogenase) or *DLD* (dihydrolipoyl dehydrogenase) showed thinner neuronal cortical layers and abnormal organization of progenitor cells, indicative of defective neurogenesis.⁹⁶ A spinal cord organoid system obtained from patient-specific iPSCs carrying the A3243G mutation in the mtDNA gene *MT-TL1* (mitochondrially encoded TRNA-Leu [UUA/G] 1) associated with the mitochondrial disease MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) also exhibited delayed neurogenesis and neurite outgrowth defects.⁹⁷ The distribution of NPCs was affected in cerebral organoids carrying LS-related mutations in the nuclear gene *SURF1* (Surfeit locus protein 1).⁹⁸ Indeed patient organoids displayed a loss of neurogenic progenitor zones, which

TABLE 1 Neurological mitochondrial diseases

| Mitochondrial disease | Main neurological symptoms | Mutated genes | Mitochondrial dysfunction |
|---|--|---|---|
| Leigh syndrome (LS) | Psychomotor regression, seizures, breathing problems, hypotonia, ataxia, lactic acidosis | <i>NDUFS1, NDUFS3, NDUFS4, NDUFS7, NDUFS8, NDUFA2, NDUFA9, NDUFA10, NDUFA12, NDUFV1, NDUFAF2, NDUFAF6, C20ORF7, FOXRED1</i> <i>SDHA</i> <i>BCS1L</i> <i>COX10, COX15</i> <i>SURF1</i> <i>TACO1</i> <i>LRPPRC</i> <i>EFG1</i> <i>C12orf65</i> <i>PDHA1</i> <i>COQ2</i> <i>AIF1</i> <i>MT-ND3, MT-ND5, MT-ND6</i> | Complex I Complex II Complex III Complex IV Complex IV Complex IV Complex IV Multiple RC complexes Multiple RC complexes PDHC CoQ Multiple RC complexes Complex I |
| Ethylmalonic encephalopathy (EE) | Microcephaly, psychomotor regression | <i>ETHE1</i> | Complex IV |
| Leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL) | Ataxia, spasticity, epilepsy, cognitive decline | <i>EARS2</i> | Multiple RC complexes |
| Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) | Ataxia, spasticity, epilepsy, cognitive decline | <i>DARS2</i> | Multiple RC complexes |
| Single OXPHOS leukoencephalopathies | Encephalopathy, ataxia, psychomotor regression | <i>NDUFS1, NDUFV1, NUBPL</i> <i>SDHAF1, SDHA, SDHB</i> <i>LYRM7</i> <i>COX6B1, SURF1, APOPT1</i> <i>PDHA1</i> <i>EF-Tu, MPV17</i> <i>NFU1, BOLA3, IBA57, ISCA2</i> | Complex I Complex II Complex III Complex IV PDH Multiple RC complexes Multiple RC complexes |
| Leber's hereditary optic neuropathy (LHON) | Vision loss | <i>MT-ND1, MT-ND4, MT-ND5, MT-ND6</i> | Complex I |
| Kearns-Sayre syndrome (KSS) | Retinal degeneration, ataxia | mtDNA deletion | Complex I-III-IV-V |
| Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) | Seizures, stroke-like episodes, cognitive regression, lactic acidosis | mtDNA point mutation | Complex I-III-IV-V |
| Myoclonic epilepsy and ragged-red fiber disease (MERRF) | Myoclonus, epilepsy, progressive ataxia, dementia | A8344G, T8356C | Multiple RC complexes |
| Maternal inherited Leigh syndrome (MILS) | Psychomotor regression | <i>MT-ATP6</i> (high heteroplasmy) | Complex V |
| Neuropathy, ataxia, and retinitis pigmentosa (NARP) | Neuropathy, ataxia, vision loss | <i>MT-ATP6</i> (low heteroplasmy) | Complex V |
| Alpers disease (MSD4A) | Seizures, dementia, spasticity, blindness | <i>POLG1</i> | Isolated or multiple RC complexes |
| Mitochondrial neurogastrointestinal | | <i>TYMP, POLG1, RRM2B</i> | Nucleoside and nucleotide pool imbalance |

(Continues)

TABLE 1 (Continued)

| Mitochondrial disease | Main neurological symptoms | Mutated genes | Mitochondrial dysfunction |
|---|---|---|-------------------------------------|
| encephalomyopathy (MNGIE) | Progressive external ophthalmoplegia, peripheral neuropathy | | |
| Navajo neurohepatopathy (NNH) | Peripheral neuropathy, leukoencephalopathy | <i>MPV17</i> | dNTP pool imbalance |
| Charcot Marie Tooth (CMT2A) | Peripheral neuropathy | <i>MFN2</i> | Bioenergetic defects |
| Dominant optic atrophy (DOA) | Optic nerve degeneration | <i>OPA1</i> | Bioenergetic defects |
| Encephalopathy due to defect in the fission of mitochondria | Psychomotor developmental delay, peripheral neuropathy | <i>DRP1</i> | Hyperfused mitochondria |
| Friedreich ataxia (FA) | Cerebellar atrophy | <i>FXN</i> | Mitochondrial iron accumulation |
| Autosomal recessive spinocerebellar ataxia (ARCA) | Ataxia, psychosis, cognitive decline | <i>PITRM1</i> | MTS and A β processing defect |
| Spastic paraplegia | Gait and limb incoordination | <i>SPG7</i> | AAA+ complex |
| CoQ10 defects | | | |
| Primary Coenzyme Q deficiencies | Encephalomyopathy, seizures, ataxia | <i>CoQ2, CoQ4, CoQ9, PDSS1, PDSS2, CABC1, ADCK3</i> | Bioenergetic defects |




FIGURE 2 Metabolic programming during neurogenesis as a target for disease intervention. Left: In healthy conditions (above), there is an orchestrated programming of energy metabolism during the generation of neurons from pluripotent stem cells (PSCs), as neural progenitor cells (NPCs) start to shift toward oxidative phosphorylation (OXPHOS) and away from glycolysis. In patients with mitochondrial diseases (below), the metabolic shift to OXPHOS may be impaired, leading to improper generation of neurons that fail to mature and fail to generate the needed branches and connections. These NPC defects may represent a potential target for disease intervention strategies aiming at reestablishing physiological neurogenesis. Right: An example of interventional strategies may be represented by the pharmacological activation of PGC-1 α , which could promote the OXPHOS shift in NPCs by increasing mitochondrial biogenesis, ultimately leading to improved generation and maturation of neurons

formed around cavities resembling embryonic-like ventricles in healthy organoids.⁹⁸ The NPC defects found in *SURF1*-mutant human organoids are in agreement with findings in *SURF1* knockout piglets,

which displayed significant reduction of the cortical thickness of the cerebral cortex gray matter at early postnatal ages and a disorganized cortical structure.⁹⁹

These findings collectively suggest that mutations associated with mitochondrial diseases could impair neurogenesis by disrupting the physiological function of NPCs. In particular, mitochondrial defects may prevent the establishment of the OXPHOS metabolic program of NPCs, which is necessary for orchestrating mammalian neurogenesis (see chapter above). NPCs from mitochondrial patients might not be able to shift their metabolism to OXPHOS, thereby causing a failure to commit to mature neurons (Figure 2). In addition, mitochondrial defects could hamper the establishment of neuronal morphogenesis and synaptogenesis that are essential for physiological brain development (see chapter above). Indeed, early neurons generated from patient-derived NPCs carrying *SURF1* mutations exhibited reduced branching outgrowth capacity and functional synaptic deficits.⁹⁸ These developmental-related disruptions in neurogenesis and morphogenesis might potentially explain the cognitive impairment that can be observed in mitochondrial patients.⁹² Hence, the mitochondrial state of NPCs may potentially represent an innovative target for interventional strategies aiming at reestablishing the physiological process of metabolic programming and the consequent instruction of human neurogenesis (Figure 2).

One potential treatment strategy targeting NPCs could be to use measures capable of promoting their metabolic shift toward OXPHOS. For example, pharmacological activation of PGC-1 α might be exploited to activate mitochondrial biogenesis, which in turn may improve the mitochondrial bioenergetic output of NPCs, thereby enhancing their ability to commit to neuronal fate and grow complex branches (Figure 2). Accordingly, genetic overexpression of PGC-1 α or pharmacological activation of PGC-1 α using the drug bezafibrate promoted OXPHOS metabolism in patient-derived NPCs carrying *SURF1* mutations, leading to improved neuronal branching formation in nascent neurons.⁹⁸ Genetic overexpression of PGC-1 α in *Surf1* knockout mice also enhanced OXPHOS activity and improved motor abilities.¹⁰⁰ PGC-1 α activation may promote synaptogenesis also by supporting astrocyte maturation.¹⁰¹ Treating human and mouse NPCs with an inductor of oxidative metabolism (called $\alpha 5$ mixture) composed by TCA cycle precursors and amino acids, also led to increased branching outgrowth and neuronal maturation.¹⁰²

This shifted view of therapeutic approaches to mitochondrial diseases might lead to novel interventions aiming at promoting the reestablishment of physiological neurogenesis rather than merely preventing the degeneration of mature neurons. The interpretation that the neuronal pathology of mitochondrial diseases is caused by neurodegeneration influenced treatment schemes centered on antioxidants to prevent the buildup of damaging ROS.⁸⁷ However, antioxidants, which may dampen physiological ROS signaling,¹⁰³ failed to consistently improve the patient symptomatology.^{88,90} Conversely, gene augmentation therapy based on the expression of a healthy copy of *SURF1* in patient NPCs improved early neuronal morphogenesis.⁹⁸ These latter results suggest that, at least in this case, the neuronal pathology of mitochondrial diseases might be caused by loss of function defects affecting neurogenesis that could be potentially restored if targeted early on.

Taken together, mitochondrial function may be crucial for the homeostasis and commitment of NPCs during the establishment of

neurogenesis. We suggest that innovative strategies of intervention against disorders impairing mitochondrial function could thus focus on enhancing the OXPHOS metabolic program of NPCs in order to promote neurogenesis and the downstream generation of functional neurons.

ACKNOWLEDGMENTS

We acknowledge support from Deutsche Forschungsgemeinschaft (DFG) (PR1527/5-1), Spark and Berlin Institute of Health (BIH) (BIH Validation Funds), German Federal Ministry of Education and Research (BMBF) (e:Bio young investigator grant AZ.031L0211), United Mitochondrial Disease Foundation (UMDF) (Roadmap for Leigh), University Hospital Düsseldorf (Forschungskommission UKD). Open Access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST

The authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS

D.B., W.D., S.L.: manuscript writing; A.P., D.B., A.Z.: figure generation. A.P.: conception, manuscript writing, final approval of manuscript.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID

Dario Brunetti  <https://orcid.org/0000-0002-2740-9370>

Alessandro Prigione  <https://orcid.org/0000-0001-9457-1952>

REFERENCES

- Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. *Annu Rev Genet.* 2005;39:359-407.
- Matilainen O, Quiros PM, Auwerx J. Mitochondria and epigenetics - crosstalk in homeostasis and stress. *Trends Cell Biol.* 2017;27:453-463.
- Dyall SD, Brown MT, Johnson PJ. Ancient invasions: from endosymbionts to organelles. *Science.* 2004;304:253-257.
- Vafai SB, Mootha VK. Mitochondrial disorders as windows into an ancient organelle. *Nature.* 2012;491:374-383.
- Zhang J, Nuebel E, Daley GQ, et al. Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. *Cell Stem Cell.* 2012;11:589-595.
- Lisowski P, Kannan P, Mlody B, et al. Mitochondria and the dynamic control of stem cell homeostasis. *EMBO Rep.* 2018;19(5):e45432.
- Sercel AJ, Carlson NM, Patananan AN, et al. Mitochondrial DNA dynamics in reprogramming to pluripotency. *Trends Cell Biol.* 2021; 31:311-323.
- Xu X, Duan S, Yi F, et al. Mitochondrial regulation in pluripotent stem cells. *Cell Metab.* 2013;18:325-332.
- Prigione A, Fauler B, Lurz R, et al. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. *STEM CELLS.* 2010;28:721-733.
- Mandal S, Lindgren AG, Srivastava AS, et al. Mitochondrial function controls proliferation and early differentiation potential of embryonic stem cells. *STEM CELLS.* 2011;29:486-495.
- Varum S, Rodrigues AS, Moura MB, et al. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. *PLoS One.* 2011;6:e20914.

12. Folmes CD, Nelson TJ, Martinez-Fernandez A, et al. Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. *Cell Metab.* 2011;14:264-271.
13. Camandola S, Mattson MP. Brain metabolism in health, aging, and neurodegeneration. *EMBO J.* 2017;36:1474-1492.
14. Iwata R, Casimir P, Vanderhaeghen P. Mitochondrial dynamics in postmitotic cells regulate neurogenesis. *Science.* 2020;369:858-862.
15. Khacho M, Harris R, Slack RS. Mitochondria as central regulators of neural stem cell fate and cognitive function. *Nat Rev Neurosci.* 2019; 20:34-48.
16. Knobloch M, Jessberger S. Metabolism and neurogenesis. *Curr Opin Neurobiol.* 2017;42:45-52.
17. Baum T, Gama V. Dynamic properties of mitochondria during human corticogenesis. *Development.* 2021;148(4):dev194183.
18. Chen LB. Mitochondrial membrane potential in living cells. *Annu Rev Cell Biol.* 1988;4:155-181.
19. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. *Annu Rev Pathol.* 2010;5:297-348.
20. Kraus F, Roy K, Pucadyil TJ, et al. Function and regulation of the divisome for mitochondrial fission. *Nature.* 2021;590:57-66.
21. Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. *Nat Rev Mol Cell Biol.* 2007;8:870-879.
22. Giacomello M, Pyakurel A, Glytsou C, et al. The cell biology of mitochondrial membrane dynamics. *Nat Rev Mol Cell Biol.* 2020;21: 204-224.
23. Kondadi AK, Anand R, Reichert AS. Cristae membrane dynamics - a paradigm change. *Trends Cell Biol.* 2020;30:923-936.
24. Cogliati S, Frezza C, Soriano ME, et al. Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. *Cell.* 2013;155:160-171.
25. Patten DA, Wong J, Khacho M, et al. OPA1-dependent cristae modulation is essential for cellular adaptation to metabolic demand. *EMBO J.* 2014;33:2676-2691.
26. Koopman WJ, Willems PH, Smeitink JA. Monogenic mitochondrial disorders. *N Engl J Med.* 2012;366:1132-1141.
27. Ghezzi D, Zeviani M. Human diseases associated with defects in assembly of OXPHOS complexes. *Essays Biochem.* 2018;62:271-286.
28. Stewart JB, Chinnery PF. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. *Nat Rev Genet.* 2015;16:530-542.
29. Zhang H, Burr SP, Chinnery PF. The mitochondrial DNA genetic bottleneck: inheritance and beyond. *Essays Biochem.* 2018;62:225-234.
30. St John JC, Ramalho-Santos J, Gray HL, et al. The expression of mitochondrial DNA transcription factors during early cardiomyocyte in vitro differentiation from human embryonic stem cells. *Cloning Stem Cells.* 2005;7:141-153.
31. Jornayvaz FR, Shulman GI. Regulation of mitochondrial biogenesis. *Essays Biochem.* 2010;47:69-84.
32. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. *Endocr Rev.* 2006;27:728-735.
33. Liang H, Ward WF. PGC-1 α : a key regulator of energy metabolism. *Adv Physiol Educ.* 2006;30:145-151.
34. Jager S, Handschin C, St-Pierre J, et al. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1 α . *Proc Natl Acad Sci USA.* 2007;104:12017-12022.
35. Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD⁺ metabolism and SIRT1 activity. *Nature.* 2009;458:1056-1060.
36. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. *Genes Dev.* 2004;18:357-368.
37. Rizzuto R, Bernardi P, Pozzan T. Mitochondria as all-round players of the calcium game. *J Physiol.* 2000;529(pt 1):37-47.
38. Gorlach A, Bertram K, Hudecova S, et al. Calcium and ROS: a mutual interplay. *Redox Biol.* 2015;6:260-271.
39. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. *Nature.* 2000;408:239-247.
40. Duchon MR. Mitochondria and calcium: from cell signalling to cell death. *J Physiol.* 2000;529(pt 1):57-68.
41. Nugud A, Sandeep D, El-Serafi AT. Two faces of the coin: mini-review for dissecting the role of reactive oxygen species in stem cell potency and lineage commitment. *J Adv Res.* 2018;14:73-79.
42. Owusu-Ansah E, Banerjee U. Reactive oxygen species prime *Drosophila* haematopoietic progenitors for differentiation. *Nature.* 2009; 461:537-541.
43. Yanes O, Clark J, Wong DM, et al. Metabolic oxidation regulates embryonic stem cell differentiation. *Nat Chem Biol.* 2010;6:411-417.
44. Armstrong L, Tilgner K, Saretzki G, et al. Human induced pluripotent stem cell lines show stress defense mechanisms and mitochondrial regulation similar to those of human embryonic stem cells. *STEM CELLS.* 2010;28:661-673.
45. Kaelin WG Jr, McKnight SL. Influence of metabolism on epigenetics and disease. *Cell.* 2013;153:56-69.
46. Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. *J Cereb Blood Flow Metab.* 2001;21:1133-1145.
47. Rangaraju V, Calloway N, Ryan TA. Activity-driven local ATP synthesis is required for synaptic function. *Cell.* 2014;156:825-835.
48. Rangaraju V, Lauterbach M, Schuman EM. Spatially stable mitochondrial compartments fuel local translation during plasticity. *Cell.* 2019; 176:73-84.
49. Rafalski VA, Brunet A. Energy metabolism in adult neural stem cell fate. *Prog Neurobiol.* 2011;93:182-203.
50. Gage FH. Mammalian neural stem cells. *Science.* 2000;287:1433-1438.
51. Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. *Nat Med.* 1998;4:1313-1317.
52. Martinez-Cerdeno V, Noctor SC. Neural progenitor cell terminology. *Front Neuroanat.* 2018;12:104.
53. Lui JH, Hansen DV, Kriegstein AR. Development and evolution of the human neocortex. *Cell.* 2011;146:18-36.
54. Gage FH. Adult neurogenesis in mammals. *Science.* 2019;364: 827-828.
55. Sorrells SF, Paredes MF, Cebrian-Silla A, et al. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. *Nature.* 2018;555:377-381.
56. Boldrini M, Fulmore CA, Tartt AN, et al. Human hippocampal neurogenesis persists throughout aging. *Cell Stem Cell.* 2018;22:589-599.
57. Tobin MK, Musaraca K, Disouky A, et al. Human hippocampal neurogenesis persists in aged adults and Alzheimer's disease patients. *Cell Stem Cell.* 2019;24:974-982.
58. Khacho M, Slack RS. Mitochondrial activity in the regulation of stem cell self-renewal and differentiation. *Curr Opin Cell Biol.* 2017;49:1-8.
59. Peppiatt C, Attwell D. Neurobiology: feeding the brain. *Nature.* 2004;431:137-138.
60. Shin J, Berg DA, Zhu Y, et al. Single-cell RNA-Seq with waterfall reveals molecular cascades underlying adult neurogenesis. *Cell Stem Cell.* 2015;17:360-372.
61. Pontzer H, Brown MH, Raichlen DA, et al. Metabolic acceleration and the evolution of human brain size and life history. *Nature.* 2016; 533:390-392.
62. Zheng X, Boyer L, Jin M, et al. Metabolic reprogramming during neuronal differentiation from aerobic glycolysis to neuronal oxidative phosphorylation. *Elife.* 2016;5:e13374.
63. Mils V, Bosch S, Roy J, et al. Mitochondrial reshaping accompanies neural differentiation in the developing spinal cord. *PLoS One.* 2015; 10:e0128130.
64. Khacho M, Clark A, Svoboda DS, et al. Mitochondrial dynamics impacts stem cell identity and fate decisions by regulating a nuclear transcriptional program. *Cell Stem Cell.* 2016;19:232-247.
65. Beckervordersandforth R, Ebert B, Schaffner I, et al. Role of mitochondrial metabolism in the control of early lineage progression and

- aging phenotypes in adult hippocampal neurogenesis. *Neuron*. 2017; 93:1518.
66. Bond AM, Ming GL, Song H. Adult mammalian neural stem cells and neurogenesis: five decades later. *Cell Stem Cell*. 2015;17:385-395.
 67. Feng W, Liu HK. Revealing the hidden powers that fuel adult neurogenesis. *Cell Stem Cell*. 2017;20:154-156.
 68. Lorenz C, Lesimple P, Bukowiecki R, et al. Human iPSC-derived neural progenitors are an effective drug discovery model for neurological mtDNA disorders. *Cell Stem Cell*. 2017;20:659-674.
 69. Le Belle JE, Orozco NM, Paucar AA, et al. Proliferative neural stem cells have high endogenous ROS levels that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner. *Cell Stem Cell*. 2011;8:59-71.
 70. Prozorovski T, Schneider R, Berndt C, et al. Redox-regulated fate of neural stem progenitor cells. *Biochim Biophys Acta*. 1850:2015: 1543-1554.
 71. La Rosa P, Bielli P, Compagnucci C, et al. Sam68 promotes self-renewal and glycolytic metabolism in mouse neural progenitor cells by modulating *Aldh1a3* pre-mRNA 3'-end processing. *Elife*. 2016;5:e20750.
 72. Rash BG, Micali N, Huttner AJ, et al. Metabolic regulation and glucose sensitivity of cortical radial glial cells. *Proc Natl Acad Sci USA*. 2018;115:10142-10147.
 73. Pereira SL, Graos M, Rodrigues AS, et al. Inhibition of mitochondrial complex III blocks neuronal differentiation and maintains embryonic stem cell pluripotency. *PLoS One*. 2013;8:e82095.
 74. Cabello-Rivera D, Sarmiento-Soto H, Lopez-Barneo J, et al. Mitochondrial complex I function is essential for neural stem/progenitor cells proliferation and differentiation. *Front Neurosci*. 2019;13:664.
 75. Journiac N, Gilabert-Juan J, Cipriani S, et al. Cell metabolic alterations due to *Mcp1* mutation in microcephaly. *Cell Rep*. 2020;31: 107506.
 76. Namba T, Doczi J, Pinson A, et al. Human-specific ARHGAP11B acts in mitochondria to expand neocortical progenitors by glutaminolysis. *Neuron*. 2020;105:867-881.
 77. Namba T, Nardelli J, Gressens P, et al. Metabolic regulation of neocortical expansion in development and evolution. *Neuron*. 2021;109: 408-419.
 78. Menon S, Gupton S. Recent advances in branching mechanisms underlying neuronal morphogenesis. *F1000Res*. 2018;7(F1000 Faculty Rev):1779.
 79. Sheng ZH. Mitochondrial trafficking and anchoring in neurons: new insight and implications. *J Cell Biol*. 2014;204:1087-1098.
 80. Shepherd GM, Harris KM. Three-dimensional structure and composition of CA3→CA1 axons in rat hippocampal slices: implications for presynaptic connectivity and compartmentalization. *J Neurosci*. 1998;18:8300-8310.
 81. Misgeld T, Schwarz TL. Mitostasis in neurons: maintaining mitochondria in an extended cellular architecture. *Neuron*. 2017;96:651-666.
 82. Spillane M, Ketschek A, Merianda TT, et al. Mitochondria coordinate sites of axon branching through localized intra-axonal protein synthesis. *Cell Rep*. 2013;5:1564-1575.
 83. Li Z, Okamoto K, Hayashi Y, et al. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. *Cell*. 2004;119:873-887.
 84. Gorman GS, Chinnery PF, DiMauro S, et al. Mitochondrial diseases. *Nat Rev Dis Primers*. 2016;2:16080.
 85. Carelli V, Chan DC. Mitochondrial DNA: impacting central and peripheral nervous systems. *Neuron*. 2014;84:1126-1142.
 86. Moran M, Moreno-Lastres D, Marin-Buera L, et al. Mitochondrial respiratory chain dysfunction: implications in neurodegeneration. *Free Radic Biol Med*. 2012;53:595-609.
 87. Viscomi C, Zeviani M. Strategies for fighting mitochondrial diseases. *J Intern Med*. 2020;287:665-684.
 88. Russell OM, Gorman GS, Lightowlers RN, et al. Mitochondrial diseases: hope for the future. *Cell*. 2020;181:168-188.
 89. Bottani E, Lamperti C, Prigione A, et al. Therapeutic approaches to treat mitochondrial diseases: "one-size-fits-all" and "precision medicine" strategies. *Pharmaceutics*. 2020;12(11):1083.
 90. Singh A, Faccenda D, Campanella M. Pharmacological advances in mitochondrial therapy. *EBioMedicine*. 2021;65:103244.
 91. Weissig V. Drug development for the therapy of mitochondrial diseases. *Trends Mol Med*. 2020;26:40-57.
 92. Falk MJ. Neurodevelopmental manifestations of mitochondrial disease. *J Dev Behav Pediatr*. 2010;31:610-621.
 93. Finsterer J. Cognitive dysfunction in mitochondrial disorders. *Acta Neurol Scand*. 2012;126:1-11.
 94. Kartsounis LD, Troung DD, Morgan-Hughes JA, et al. The neuropsychological features of mitochondrial myopathies and encephalomyopathies. *Arch Neurol*. 1992;49:158-160.
 95. Ma H, Folmes CD, Wu J, et al. Metabolic rescue in pluripotent cells from patients with mtDNA disease. *Nature*. 2015;524:234-238.
 96. Romero-Morales AI, Rastogi A, Temuri H, et al. Human iPSC-derived cerebral organoids model features of Leigh Syndrome and reveal abnormal corticogenesis. *bioRxiv*, 2020.04.21.054361.
 97. Winanto KZJ, Soh BS, et al. Organoid cultures of MELAS neural cells reveal hyperactive Notch signaling that impacts neurodevelopment. *Cell Death Dis*. 2020;11:182.
 98. Inak G, Rybak-Wolf A, Lisowski P, et al. Defective metabolic programming impairs early neuronal morphogenesis in neural cultures and an organoid model of Leigh syndrome. *Nat Commun*. 2021;12.
 99. Quadalti C, Brunetti D, Lagutina I, et al. SURF1 knockout cloned pigs: early onset of a severe lethal phenotype. *Biochim Biophys Acta Mol Basis Dis*. 1864:2018:2131-2142.
 100. Viscomi C, Bottani E, Civiletto G, et al. In vivo correction of COX deficiency by activation of the AMPK/PGC-1 α axis. *Cell Metab*. 2011;14:80-90.
 101. Zehnder T, Petrelli F, Romanos J, et al. Mitochondrial biogenesis in developing astrocytes regulates astrocyte maturation and synapse formation. *Cell Rep*. 2021;35:108952.
 102. Bifari F, Dolci S, Bottani E, et al. Complete neural stem cell (NSC) neuronal differentiation requires a branched chain amino acids-induced persistent metabolic shift towards energy metabolism. *Pharmacol Res*. 2020;158:104863.
 103. Dogan SA, Cerutti R, Beninca C, et al. Perturbed redox signaling exacerbates a mitochondrial myopathy. *Cell Metab*. 2018;28: 764-775.

How to cite this article: Brunetti D, Dykstra W, Le S, Zink A, Prigione A. Mitochondria in neurogenesis: Implications for mitochondrial diseases. *Stem Cells*. 2021;1-9. <https://doi.org/10.1002/stem.3425>